SEC Form 4 · accession 0001562180-19-000861
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Haddock
Officer — CFO
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 6:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | S | 11,712 | $20.00 | D | 30,059 | D | |
| Common Stock | Feb 7, 2019 | M | 85,000 | $3.77 | A | 115,059 | D | |
| Common StockF2 | Feb 7, 2019 | S | 85,000 | $22.0506 | D | 30,059 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.77 | Feb 7, 2019 | M | 85,000 | D | — | Jul 28, 2026 | Common Stock | 85,000 | 404,450 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $22.00 to $22.12. Details of actual prices for shares sold are available from the Issuer upon request.
- F3The options vest in four equal annual installments beginning on July 28, 2017.